Skip to main content

Table 1 Completion of the three PRO instruments at each assessment during the study

From: Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias

Week

mSICT

Palatability

GI Symptom Diary*

Deferasirox DT

N = 86

n (%)

Deferasirox FCT

N = 87

n (%)

Deferasirox DT

N = 86

n (%)

Deferasirox FCT

N = 87

n (%)

Deferasirox DT

N = 86

n (%)

Deferasirox FCT

N = 87

n (%)

−2

    

60 (69.8)

59 (67.8)

−1

    

62 (72.1)

52 (59.8)

1

    

70 (81.4)

69 (79.3)

2

70 (81.4)

70 (80.5)

69 (80.2)

70 (80.5)

65 (75.6)

71 (81.6)

3

58 (67.4)

51 (58.6)

57 (66.3)

51 (58.6)

64 (74.4)

66 (75.9)

4

    

60 (69.8)

64 (73.6)

5

    

58 (67.4)

64 (73.6)

6

    

64 (74.4)

57 (65.5)

7

    

57 (66.3)

53 (60.9)

8

    

59 (68.6)

51 (58.6)

9

    

55 (64.0)

49 (56.3)

10

    

53 (61.6)

49 (56.3)

11

    

51 (59.3)

44 (50.6)

12

    

51 (59.3)

45 (51.7)

13

59 (68.6)

64 (73.6)

59 (68.6)

62 (71.3)

49 (57.0)

50 (57.5)

14

    

51 (59.3)

44 (50.6)

15

    

49 (57.0)

43 (49.4)

16

    

48 (55.8)

41 (47.1)

17

    

44 (51.2)

40 (46.0)

18

    

44 (51.2)

38 (43.7)

19

    

40 (46.5)

37 (42.5)

20

    

40 (46.5)

39 (44.8)

21

    

39 (45.3)

37 (42.5)

22

    

38 (44.2)

35 (40.2)

23

    

36 (41.9)

34 (39.1)

24

63 (73.3)

60 (69.0)

63 (73.3)

60 (69.0)

32 (37.2)

26 (29.9)

  1. SOT for the mSICT and palatability were defined as the first PRO assessment at week 2 (or week 3 if missing); for the GI Symptom Diary, week 1 was taken as SOT; *includes patients with at least four complete daily responses. DT Dispersible tablet, FCT Film-coated tablet, GI Gastrointestinal, PRO Patient-reported outcome, mSICT modified Satisfaction with iron chelation therapy, SOT Start of treatment